Antiemetic Therapy in Pediatric Traumatic Brain Injury

Introduction to Alternative Antiemetics

The American Society of Clinical Oncology notes that adding dexamethasone significantly improves antiemetic efficacy in patients with nausea, particularly when combined with other antiemetics 1

Granisetron is another 5-HT3 receptor antagonist with similar mechanism to ondansetron and may be more effective in some contexts, available as oral tablets, liquid formulation, or transdermal patch 1, 2
If ondansetron is contraindicated due to QT prolongation concerns or allergy, granisetron represents the most logical alternative as it shares the same favorable neurological safety profile 1, 2
Dexamethasone can be highly effective for nausea, particularly when combined with other antiemetics, and may serve dual purposes in pediatric TBI: reducing cerebral edema while providing antiemetic effects 3, 4
Prochlorperazine can cause extrapyramidal symptoms and sedation, making it problematic for neurological monitoring in TBI patients, and its use is generally not recommended as a first-line treatment 3, 4

The American Society of Clinical Oncology recommends adding dexamethasone to improve antiemetic efficacy in patients with increased intracranial pressure or bowel obstruction 1
Dexamethasone may be used as an adjunctive therapy to provide antiemetic effects without neurological interference, and may benefit cerebral edema in pediatric TBI patients 3, 4

The American Academy of Pediatrics recommends using ondansetron as the first-line antiemetic for children with traumatic brain injury presenting with nausea or vomiting, due to its superior safety profile compared to alternatives like metoclopramide, particularly regarding effects that could interfere with neurological monitoring 5

Dopamine antagonists, such as metoclopramide, should not be used for multiple consecutive days in pediatric patients due to the high incidence of dystonic reactions 6
Exercise caution in children with pre-existing heart disease, as QT prolongation risk remains a theoretical concern 5

The American College of Clinical Pharmacy recommends using weight-based dosing for optimal efficacy and safety, with intravenous doses of 0.1-0.15 mg/kg and oral doses of 0.1 mg/kg or surface area-based dosing (5 mg/m²) 5
Children may require higher weight-based doses than adults due to pharmacokinetic variations 7, 6
In severe hepatic impairment, do not exceed 8 mg total daily dose 5

Ensure adequate hydration before or during ondansetron administration, and monitor electrolytes, particularly potassium and magnesium, as abnormalities can increase QT prolongation risk 5
Obtain baseline ECG if patient has known cardiac disease 5